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Cancerdiagnosisisimportant,andthe early diagnosisofcancers could predict a moresuccessful treatment. The proteomicstudies
emerged to be useful in combined analyses of samples from patients and provide more accurate diagnosis when compared to the
single-factor-based diagnosis. In recent years, cancer detection with surface-enhanced laser desorption/ionization time of ﬂight
mass spectrometry (SELDI-TOF MS) is ﬂourishing and brought signiﬁcant progress in this area. This paper summarizes some
recent results with this technique for cancer diagnosis.
1.Introduction
Cancer diagnosis is important, and the early diagnosis of
cancers could predict a more successful treatment. The accu-
rate diagnosis of cancers before the appearance of symptoms
often relies on the identiﬁcation of reliable biomarkers. Fur-
ther, these biomarkers reﬂecting the progression of cancers
suggest the etiology of the disease. Proteomics technology
has emerged to be important tools in cancer diagnosis and
evaluation tools during treatment through the analyses of
changes in cancer biomarkers. The fact that people have
identiﬁed diverse biomarkers during the development and
progression of diﬀerent cancers suggested that the speciﬁcity
and abundance of many small proteins could reﬂect the
current state of cancer progression, and even predict the
treatment eﬃcacy. From serum, saliva, urine, and so forth,
people could acquire the complete proteome that reﬂect
the dynamic proteomics of the patients with high accuracy;
and proteomic analyses permit the combined comparison
of several biomarkers at the same time, which could ﬁnally
bring convincing results. This included two-dimensional
gel electrophoresis (2-DE), one-or two-dimensional liquid
chromatographic (LC-MS), and surface-enhanced laser des-
orption/ionization time of ﬂight mass spectrometry (SELDI-
TOF MS). In the present paper we review the progresses
achieved in using SELDI-TOF MS technology for cancer
biomarker proﬁling and detection.
2.IntroductiontoSELDI-TOFMS
TheSELDI-TOFMStechniquewasﬁrstly introducedin1993
[1] and was commercialized by Ciphergen Biosystems in
1997 as the ProteinChip system. SELDI-TOF-MS is one type
of variation of matrix-assisted laser desorption/ionization
(MALDI) that uses a target modiﬁed to reach biochemical
aﬃnity with the sample proteins. The diﬀerences between
the two techniques are the following. In MALDI, the sample
is mixed with the matrix molecule in solution, and a small
amount of the mixture was deposited on a surface to
dry. This made the sample and matrix cocrystallized after
the solvent evaporated. On the other hand, in SELDI, the
mixture is spotted on a surface modiﬁed with a chemical
functionality such as binding aﬃnity. Without being dried,
some proteins in the samples would bind to the modiﬁed2 Journal of Biomedicine and Biotechnology
surface, while the others were washed oﬀ. Then the matrix
is applied to the surface for crystallization with the sample
peptides. In the binding and washing oﬀ steps the surface-
bound proteins are left for analyses. Samples spotted on an
SELDI surface were typically analyzed with time-of-ﬂight
mass spectrometry (TOF-MS) [2]. A laser-ionized peptides
from crystals of the sample and matrix mixture. These ions
were thenacceleratedthrough anelectric ﬁeldand downinto
the ﬂight tube. Finally, the detector would measure ions as
theyreachtheendofthetube(Figure 1).Themass-to-charge
ratio of each ion could be determined from the length of the
tube,thekinetic energy giventoions by theelectric ﬁeld, and
the time taken to travel the length of the tube. Some surfaces
that were normally adopted include CM10 (weak-positive
ion exchange), H50 (hydrophobic surface, similar to C6-C12
reverse phase chromatography), IMAC30 (metal-binding
surface), and Q10 (strong anion exchanger). Surfaces can
also be modiﬁed or functionalized with antibodies, other
proteins with proper binding properties, or even DNA.
3.BodyFluidsasImportant SELDI-TOF
MS Samples
OneofthekeyfeaturesofSELDI-TOFMSisthelittlerequire-
mentofsample puriﬁcationorproteinseparationsbeforethe
MS analyses. With high sensitivity to low-molecular-weight
proteins (less than 15kda), SELDI-TOF MS could detect
some biomarkers that were neglected in other proteomic
analyses suchas2D-gels[3,4].Inﬁnding samplesforSELDI-
TOF MS analysis, both tissue extracts and body ﬂuids could
be used. In past studies, the analyzed body ﬂuids include
plasma, serum, urine, saliva, amniotic ﬂuid, cerebrospinal
liquid, bronchoalveolar wash out, tears, and nipple aspirate
ﬂuid [5–23]. Among these choices, serum, urine, saliva, and
plasma were most widely used.
The challenge that biomarker proteins only take a
very small proportion in total plasma proteins—less than
one percent suggested that MS is more suitable in cancer
detection in compared to other less sensitive approaches
[24]. Moreover, the levels of proteins could vary according
to the environmental stress, codiseased disorders or previous
drug treatments [24, 25]. Sometimes, the proteins were
modiﬁed orcleavedby enzymes, which further decreased the
amount of biomarkers for detection in body ﬂuids. All these
diﬃculties suggested that cancer detection should adopt
SELDI-TOF MS technique with high sensitivity and without
the need of previous protein puriﬁcation from samples.
Consistently,itwasshowedthatthehighlyabundantproteins
in the serum such as albumin and immunoglobulin could be
well separated from potential markers without causing any
inference [16, 26–29].
4.CancerDiagnosis
Many types of cancers could be and have been diagnosed
with SELDI-TOF MS technology. It is possible to read the
diﬀerent peaks in samples from control and patients, as
shown in Figure 2. In the paragraphs below, we selected
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Figure 1: After the samples were dried, a laser-ionized peptides
from crystals of the sample and matrix mixture. Then, these ions
wereacceleratedthroughanexternalelectricﬁeldanddownintothe
ﬂight tube. Finally, the detector would measure ions as they reach
the end of the tube with software readout the data.
ovarian cancer, breast cancer, prostate cancer, and hepato-
cellular cancer as examples showing how the new technique
promoted the diagnosis of these cancers.
4.1. Ovarian Cancer. It was found that early diagnosed
(phase I) ovarian cancer patients have the 5-year survival
rates more than 90%, which is 35% in most middle-late
phase cases [30, 31]. Some studies tried to diagnose phase
I patients accurately. For instance, one study adopted C16
surface chips with SELDI-TOF MS in analyzing 50 patient
cases and found a diﬀerent pattern of proteome including
ﬁve peaks at 534, 989, 21 11, 2251, and 2465, respectively,
[31, 32]. In most of these studies, the method could reach
diagnosis accuracy, sensitivity, and speciﬁcity of more than
99%, especially when combined with improved statistical
methods [33–40]. Taken together, SELDI-TOF MS could be
an important and very accurate tool in diagnosing ovarian
cancer patients, both in early and advanced stages.
4.2. Breast Cancer. X-ray examination was now routinely
adopted for women aged more than 40 years old however,
the accuracy is only around 50%. There were some available
biomarkers in serum for breast cancer diagnosis, such as
CA15.3,but with lowsensitivity (23%) and speciﬁcity (69%)
[41, 42]. In one study that combined IMAC-Ni2+ chip with
SELDI-TOF MS, the authors showed three protein spectrum
peaks at 4.3, 8.1, and 8.92kda, respectively, combined
analyses with the three peaks in 169 cases (103 patient cases)
and showed the diagnosis sensitivity 93% and speciﬁcity
96% [43]. In other studies, many other potential biomarkers
have been identiﬁed, and reached high accuracy in diagnosis
[44–55], and combined analyses of these biomarkers could
further improve the sensitivity and speciﬁcity.
4.3. Prostate Cancer. Prostate-speciﬁc antigen (PSA) has
been widely used in prostate cancer diagnosis with relatively
high sensitivity but quite low speciﬁcity [56, 57] ￿95% and
18%, respectively, as shown in one previous study [58].
Many studies have adopted SELDI-TOF MS to ﬁnd better
biomarker for early prostate cancer diagnosis [59–68]. OneJournal of Biomedicine and Biotechnology 3
2500 5000 7500 10000 12500 15000
2500 5000 7500 10000 12500 15000
Sample
Sample
0
20
40
60
(a)
(
O
)
(
O
)
0
20
40
0
20
40
2000 4000 6000 8000 10000
2000 4000 6000 8000 10000
Control
CRC
2871.7+H
3938.3+H
4967.3+H
8565.8+H
(b)
Figure 2: Samples from control and colorectal cancer patients
showeddiﬀerent peaks inproteomicsspectrum. Somechangeswere
highlighted.
studycomparedserumsamplesfromprostatecancerpatients
and patients with other prostate diseases for SELDI-TOF MS
analyses; they found several biomarkers including PC1, PC2,
and PC3, with higher sensitivity when compared to PSA-
based diagnosis in the study involved in more than 300 cases
[69]. The serum-based proteomic analysis would become
one of the major diagnosis tools for prostate cancer in the
future.
4.4. Hepatocellular Cancer. Hepatocellular cancer (HCC) is
the most common primary malignant tumor of the liver.
Primary liver cancer accounts for less than 1% of all cancers
in states, however, in past decades, this increased due to
a large pool of people with longstanding hepatitis C virus
infection. This is even worse in China and many developing
countries. The detection of HCC could be very diﬃcult,
as most patients onset without any symptoms. Ultrasound
detection and alpha-fetoprotein (AFP) in the serum were
used in past studies [71, 72]. However, it should be noted
that serum AFP levels were normal in 40% patients with
<2cm (in diameter) hepatocellular carcinoma and in 28%
of those with tumors 2 to 5cm in diameter. Additionally,
not all hepatocellular carcinomas secrete AFP such as the
Fibrolamellar type. The AFP levels could also be elevated
in pregnancy, other gonadal originated tumors, and even
in acute or chronic liver diseases (CLD) without tumor. All
of these weakened the sensitivity and speciﬁcity of AFP as
serum biomarkers for HCC.
SELDI-TOFMS havebeenadoptedtoﬁnd new biomark-
ers for HCC diagnosis [71, 73–82]. In another study, the
authors adopted the multidimensional separated statistics
in analyzing the proteomics data and showed diagnosis
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Figure 3: This represented the reproducibility of four separate
analyses from the healthy controls of blood type O, suggesting the
high reliability of SELDI-TOF MS in serum sample analyses [70].
speciﬁcity of 90% and sensitivity of 92% in separating
HCC out of CLD, which could not be reached with AFP
examination [83].More interestingly, theirworks showed the
proteomics between subtypes of HCC: the progressive one
and the metastasis one. All these data could provide new
hopes for accurate and early detection of HCC in patients or
people living in areas with hepatitis B and C virus infection.
It should be noted that in practice, the combined use
of several potential biomarkers could greatly increase the
speciﬁcity and sensitivity of cancer diagnosis [46, 84–88].
It is now convenient to set up the diagnostic tree with
software, and the diagnosis automatically follows. These
selected combinations could be considered as a group of
biomarkers representing the etiology of cancer in given
population, which might provide some rationale bases for
therapeutic developments.
5.Summary
In this paper, we brieﬂy summarized the recent progresses
achieved in cancer detection and diagnosis with SELDI-TOF
MS technique.The use ofbody ﬂuids and tissue extracts with
lowproteinscontentassamplesinthistechnologyissuperior
to many other available proteomic approaches. Moreover,
SELDI-TOFMSis very sensitive and reliable inrepeated tests
(Figure 3)[ 70]. It should also be noted that SELDI-TOF-
MS could also contribute to the ongoing human proteome
studies, as proposed for the total proteins in the serum
[2,29,89].Whencombinedwithradiologicaldata,thiscould
ﬁnally bring patients new hopes in the early detection of
the tumors inside even before the onset of symptoms. For
instance, the detection of speciﬁc changes in one protein
might point out the potential regions of cancer genesis and,
therefore, suggest the regions of interest for radiologist; also,
when unknown tissues were identiﬁed in the radiological
report, the accurate SELDI-TOF-MS could be used to verify
the existence of a tumor. We believe that SELDI-TOF-MS4 Journal of Biomedicine and Biotechnology
would become one of the most powerful tools in early cancer
diagnosis in coming days.
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